AKERO THERAPEUTICS IN

In Akero Therapeutics’ Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks

13 Sep 2022 06:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present Results from Phase 2b HARMONY Trial Investigating Efruxifermin in Patients with Pre-Cirrhotic NASH

08 Sep 2022 16:01:00 By Nasdaq GlobeNewswire

Study Published in JHEP Reports Shows Efruxifermin Rapidly Improved Fibrosis in Cirrhotic NASH patients After 16 Weeks of Treatment

24 Aug 2022 08:00:01 By Nasdaq GlobeNewswire

Akero Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

04 Aug 2022 16:05:37 By Nasdaq GlobeNewswire

Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH Fibrosis

27 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million

16 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at Keystone Symposium on Efruxifermin as a Therapy for NASH

13 Jun 2022 08:00:01 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

01 Jun 2022 16:05:00 By Nasdaq GlobeNewswire

Akero Therapeutics Reports First Quarter 2022 Financial Results

06 May 2022 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at Upcoming Healthcare Conferences in May

02 May 2022 07:30:00 By Nasdaq GlobeNewswire

Akero Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

25 Feb 2022 07:00:00 By Nasdaq GlobeNewswire

Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH Patients

08 Feb 2022 08:00:03 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

04 Jan 2022 16:05:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the Evercore ISI 4th Annual HealthCONx Virtual Conference

26 Nov 2021 17:28:49 By Nasdaq GlobeNewswire

Akero Presents New Analysis of Phase 2a BALANCED Study Data Showing Additional Qualitative Evidence of Histological Improvement in EFX-treated NASH Patients after 16 Weeks of Treatment

12 Nov 2021 08:01:00 By Nasdaq GlobeNewswire

Akero Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

12 Nov 2021 07:00:02 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the Jefferies London Healthcare Conference

09 Nov 2021 16:15:00 By Nasdaq GlobeNewswire

Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH

19 Oct 2021 16:15:00 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the H.C. Wainwright 5th Annual NASH Investor Conference

05 Oct 2021 08:00:01 By Nasdaq GlobeNewswire

Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference

07 Sep 2021 08:00:02 By Nasdaq GlobeNewswire